Acute coronary syndromes: Targeting inflammation - What has the VISTA-16 trial taught us?

Nature Reviews Cardiology

Volumn 11, Issue 3, 2014, Pages 130-132

  Odonoghue, Michelle L ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E; ATORVASTATIN; C REACTIVE PROTEIN; DARAPLADIB; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; SECRETORY PHOSPHOLIPASE A2; VARESPLADIB;

ACUTE CORONARY SYNDROME; ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; DRUG SAFETY; ENZYME INHIBITION; FOAM CELL; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; IN VITRO STUDY; INFLAMMATION; MACROPHAGE; MUSCLE NECROSIS; NONHUMAN; PERCUTANEOUS CORONARY INTERVENTION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PLEIOTROPY; PRIORITY JOURNAL; REPERFUSION INJURY; REVIEW; STENT THROMBOSIS; THROMBOCYTE FUNCTION; UNSTABLE ANGINA PECTORIS;

ACETATES; ACUTE CORONARY SYNDROME; FEMALE; HUMANS; INDOLES; MALE; MYOCARDIAL INFARCTION; PHOSPHOLIPASES A;

EID: 84896733435     PISSN: 17595002     EISSN: 17595010     Source Type: Journal    
DOI: 10.1038/nrcardio.2013.220     Document Type: Review

References (10)

1. Nicholls, S. J. et al. Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial. JAMA http://dx.doi.org/10.1001/jama.2013.282836.
2. Mallat, Z., Lambeau, G. & Tedgui, A. Lipoprotein-associated and secreted phospholipases A2 in cardiovascular disease: roles as biological effectors and biomarkers. Circulation 122, 2183-2200 (2010).
3. Rosenson, R. S. & Hurt-Camejo, E. Phospholipase A2 enzymes and the risk of atherosclerosis. Eur. Heart J. 33, 2899-2909 (2012).
4. Shaposhnik, Z., Wang, X., Trias, J., Fraser, H. & Lusis, A. J. The synergistic inhibition of atherogenesis in apoE-/- mice between pravastatin and the sPLA2 inhibitor varespladib (A-002). J. Lipid Res. 50, 623-629 (2009).
5. Fujioka, D. et al. Reduction in myocardial ischemia/reperfusion injury in group X secretory phospholipase A2-deficient mice. Circulation 117, 2977-2985 (2008).
6. Cannon, C. P. et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N. Engl. J. Med. 350, 1495-1504 (2004).
7. Schwartz, G. G. et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 285, 1711-1718 (2001).
8. Dzavik, V. et al. The sPLA2 Inhibition to Decrease Enzyme Release after Percutaneous Coronary Intervention (SPIDER-PCI) trial. Circulation 122, 2411-2418 (2010).
9. Holmes, M. V. et al. Secretory phospholipase A2-IIA and cardiovascular disease: a Mendelian randomization study. J. Am. Coll. Cardiol. 62, 1966-1976 (2013).
10. GlaxoSmithKline. GSK announces top-line results from pivotal Phase III study of darapladib in chronic coronary heart disease [online], http://ww.gsk.com/media/press-releases/2013/gsk-announces-top-line-results-from- pivotal-phase-iii-study-of-d.html (2013).